Scalper1 News
Shares of Gilead Sciences (GILD) are down amid news that the drugmaker is reportedly nearing a licensing deal to bring its blockbuster hepatitis C drug Sovaldi to developing countries such as India and Pakistan. Generic drugmakers would be able to manufacture the best-selling hepatitis C therapy as well as an experimental Sovaldi hybrid, according to Bloomberg. Pricing is a sore spot for Gilead, as much has been made about the drug’s $1,000-a-pill Scalper1 News
Scalper1 News